[
  {
    "ts": null,
    "headline": "August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys",
    "summary": "Discover the top Dow dividend stocks for steady gains by 2026.",
    "url": "https://finnhub.io/api/news?id=5b4324cf7aa0db1844e537f7ec31acf7b22ccb8eb46fc4995dc453357313aa09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754569431,
      "headline": "August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys",
      "id": 136249581,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/481098702/image_481098702.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Discover the top Dow dividend stocks for steady gains by 2026.",
      "url": "https://finnhub.io/api/news?id=5b4324cf7aa0db1844e537f7ec31acf7b22ccb8eb46fc4995dc453357313aa09"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (AMGN) Completes US$60,594 Million Share Buyback After 14 Years",
    "summary": "Amgen (AMGN) recently concluded a buyback period without repurchasing any shares, maintaining its focus on prior buyback strategies. The company's positive earnings announcement highlighted robust year-over-year growth, potentially contributing to its stock price increase of 4.6% over the last quarter. Despite legal issues impacting the broader perception of companies engaged in antitrust activities, Amgen’s legal challenges might have countered market trends. Additionally, ongoing product...",
    "url": "https://finnhub.io/api/news?id=73a97afd1e3cfc7f55e82556aa480e04741d46d75c0123376c8e8228a9084dfb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754544127,
      "headline": "Amgen (AMGN) Completes US$60,594 Million Share Buyback After 14 Years",
      "id": 136246349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) recently concluded a buyback period without repurchasing any shares, maintaining its focus on prior buyback strategies. The company's positive earnings announcement highlighted robust year-over-year growth, potentially contributing to its stock price increase of 4.6% over the last quarter. Despite legal issues impacting the broader perception of companies engaged in antitrust activities, Amgen’s legal challenges might have countered market trends. Additionally, ongoing product...",
      "url": "https://finnhub.io/api/news?id=73a97afd1e3cfc7f55e82556aa480e04741d46d75c0123376c8e8228a9084dfb"
    }
  }
]